NetworkNewsBreaks – Oncotelic Therapeutics, Inc.
Post# of 76
(Total Views: 57)
Posted On: 11/20/2025 4:58:53 PM
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Preliminary $1.7B Pipeline Valuation From Joint Venture Partner
Oncotelic Therapeutics (OTCQB: OTLC) today announced that joint venture partner GMP Bio has received an independent Frost & Sullivan (Hong Kong) valuation estimating the potential value of its therapeutic pipeline at approximately $1.7 billion, implying about $765 million for Oncotelic’s 45% stake. The non-binding, forward-looking analysis does not represent fair value under U.S. GAAP, and Oncotelic has initiated a separate ASC-compliant valuation that will support future financial reporting. Depending on the results, the Company may record a higher carrying value for its minority interest in upcoming periods, consistent with applicable fair-value measurement standards. CEO Dr. Vuong Trieu said the valuation affirms progress across the OT-101 program and the Deciparticle(TM) platform, with the JV advancing OT-101 into Phase 3 PDAC and Phase 2 combination trials, expanding its nanomedicine pipeline, and operating a GMP-licensed facility in San Diego. The JV is preparing for a potential Hong Kong IPO in late 2026, subject to market and regulatory conditions.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Oncotelic Therapeutics (OTCQB: OTLC) today announced that joint venture partner GMP Bio has received an independent Frost & Sullivan (Hong Kong) valuation estimating the potential value of its therapeutic pipeline at approximately $1.7 billion, implying about $765 million for Oncotelic’s 45% stake. The non-binding, forward-looking analysis does not represent fair value under U.S. GAAP, and Oncotelic has initiated a separate ASC-compliant valuation that will support future financial reporting. Depending on the results, the Company may record a higher carrying value for its minority interest in upcoming periods, consistent with applicable fair-value measurement standards. CEO Dr. Vuong Trieu said the valuation affirms progress across the OT-101 program and the Deciparticle(TM) platform, with the JV advancing OT-101 into Phase 3 PDAC and Phase 2 combination trials, expanding its nanomedicine pipeline, and operating a GMP-licensed facility in San Diego. The JV is preparing for a potential Hong Kong IPO in late 2026, subject to market and regulatory conditions.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)